Invokana (in-vo-KAHN-uh, canagliflozin) as the first in a new class of oral drugs for type 2 diabetes

Reps will promote Invokana (in-vo-KAHN-uh, canagliflozin) as the first in a new class of oral drugs for type 2 diabetes.

Invokana is the first "SGLT2 inhibitor" to hit the market. It helps the kidneys get rid of excess sugar by sending it out in the urine instead of being reabsorbed.

It can be used alone for treating type 2 diabetes...in combo with metformin...or with metformin plus other second-line options such as gliclazide, pioglitazone, and insulin.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote